HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

K Kugiyama Selected Research

Muscle Spasticity (Spastic)

9/2001Enhanced platelet aggregation in the coronary circulation after coronary spasm.
3/2001Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.
2/2001Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina.
2/2001Nitric oxide-mediated vasodilatation is decreased in forearm resistance vessels in patients with coronary spastic angina.
1/2001Glutathione attenuates coronary constriction to acetylcholine in patients with coronary spastic angina.
8/2000Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina.
7/2000Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
6/2000Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species.
3/2000Elevated levels of soluble intercellular adhesion molecule-1 in the coronary circulation of patients with coronary organic stenosis and spasm.
2/2000Formation of platelet aggregates after attacks of coronary spastic angina pectoris.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


K Kugiyama Research Topics

Disease

11Muscle Spasticity (Spastic)
09/2001 - 01/2000
10Spasm (Spasms)
09/2001 - 01/2000
5Myocardial Ischemia (Ischemic Heart Diseases)
12/2001 - 01/2000
4Coronary Vasospasm (Coronary Artery Vasospasm)
09/2001 - 01/2000
3Coronary Artery Disease (Coronary Atherosclerosis)
12/2001 - 07/2000
3Unstable Angina
09/2001 - 10/2000
3Myocardial Infarction
04/2001 - 01/2000
3Heart Failure
01/2001 - 05/2000
3Hypertension (High Blood Pressure)
01/2001 - 01/2000
3Pathologic Constriction (Stenosis)
09/2000 - 01/2000
2Chest Pain (Chest Pains)
09/2001 - 09/2001
2Angina Pectoris
04/2001 - 01/2001
2Atherosclerosis
03/2001 - 10/2000
2Thrombosis (Thrombus)
03/2001 - 02/2001
2Cardiovascular Diseases (Cardiovascular Disease)
02/2001 - 01/2000
2Diabetes Mellitus
09/2000 - 01/2000
2Insulin Resistance
09/2000 - 06/2000
1Hypercholesterolemia
12/2001
1Sudden Death
04/2001
1Hyperventilation
03/2001
1Left Ventricular Dysfunction
01/2001
1Hyperemia
01/2001
1Cardiomegaly (Heart Hypertrophy)
01/2001
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
11/2000
1Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
11/2000
1Atherosclerotic Plaque (Atheroma)
10/2000
1Stable Angina
10/2000
1Glucose Intolerance
09/2000
1Acute Coronary Syndrome
09/2000
1Hyperplasia
08/2000
1Hyperinsulinism (Hyperinsulinemia)
06/2000
1Coronary Disease (Coronary Heart Disease)
06/2000
1Hyperglycemia
03/2000
1Vascular Diseases (Vascular Disease)
01/2000
1Coronary Stenosis (Coronary Artery Stenosis)
01/2000
1Hypoxia (Hypoxemia)
01/2000

Drug/Important Bio-Agent (IBA)

5Acetylcholine (Acetylcholine Chloride)FDA Link
09/2001 - 01/2000
4Nitric Oxide (Nitrogen Monoxide)FDA Link
02/2001 - 06/2000
3Plasminogen InactivatorsIBA
09/2001 - 01/2000
3Atrial Natriuretic Factor (ANF)IBA
01/2001 - 09/2000
3Natriuretic PeptidesIBA
11/2000 - 05/2000
3Glucose (Dextrose)FDA LinkGeneric
09/2000 - 03/2000
2CholesterolIBA
12/2001 - 01/2000
2oxidized low density lipoproteinIBA
03/2001 - 02/2001
2LDL Lipoproteins (beta Lipoproteins)IBA
03/2001 - 02/2001
2AntioxidantsIBA
01/2001 - 06/2000
2Secretory Phospholipases A2IBA
10/2000 - 07/2000
2C-Reactive ProteinIBA
10/2000 - 07/2000
2Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
09/2000 - 09/2000
2LDL CholesterolIBA
09/2000 - 01/2000
2Reactive Oxygen Species (Oxygen Radicals)IBA
09/2000 - 06/2000
2Ascorbic Acid (Vitamin C)FDA LinkGeneric
09/2000 - 06/2000
2LipidsIBA
07/2000 - 01/2000
1Lipoproteins (Lipoprotein)IBA
12/2001
1Hormones (Hormone)IBA
12/2001
1Estrogens (Estrogen)FDA Link
12/2001
1Indicators and Reagents (Reagents)IBA
09/2001
1Thromboplastin (Tissue Factor)IBA
09/2001
1Thomsen-Friedenreich antigenIBA
09/2001
1Malondialdehyde (Propanedial)IBA
03/2001
1AutoantibodiesIBA
03/2001
1EnzymesIBA
03/2001
1Estradiol (Delestrogen)FDA LinkGeneric
03/2001
1Immunoglobulin G (IgG)IBA
03/2001
1ImmunosorbentsIBA
03/2001
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2001
1AldosteroneIBA
01/2001
1Glutathione (Reduced Glutathione)IBA
01/2001
1Thiobarbituric Acid Reactive SubstancesIBA
01/2001
1Phospholipases A2 (Phospholipase A2)IBA
10/2000
1Phospholipases (Phospholipase)IBA
07/2000
1Hydrocortisone (Cortisol)FDA LinkGeneric
05/2000
1Biomarkers (Surrogate Marker)IBA
05/2000
1Dehydroepiandrosterone SulfateIBA
05/2000
1Brain Natriuretic Peptide (Natrecor)FDA Link
05/2000
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
03/2000
1NF-kappa B (NF-kB)IBA
01/2000
1DobutamineFDA LinkGeneric
01/2000
1Tissue Plasminogen Activator (Alteplase)FDA Link
01/2000
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2000
1AntigensIBA
01/2000

Therapy/Procedure

3Lasers (Laser)
02/2001 - 02/2000
1Therapeutics
09/2001
1Coronary Artery Bypass (Coronary Artery Bypass Surgery)
04/2001
1Length of Stay
02/2001
1Aftercare (After-Treatment)
09/2000